Newron Pharmaceuticals

Historical price data

Newron Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing new treatments for patients with diseases of the central and peripheral nervous system. Its key achievement is the development and approval of Xadago® (safinamide), a once-daily oral add-on therapy for Parkinson's disease patients experiencing motor fluctuations. The company's strategy focuses on leveraging its expertise in neurology to advance a pipeline of novel compounds for rare and underserved neurological conditions, including Rett syndrome and other rare epilepsies.

Focus on novel mechanism discovery in neuroscience, developing first-in-class compounds that modulate novel targets for central and peripheral nervous system disorders.

22 drugs in pipeline, 11 in Phase 3

Total raised: $25M

In Parkinson's, Xadago competes with other MAO-B inhibitors and add-on therapies. In its pipeline areas, Evenamide faces competition from clozapine and other emerging schizophrenia treatments, while Sarizotan competes with recently approved trofinetide and other investigational Rett syndrome therapies. Differentiation is based on novel mechanisms of action.